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OBJECTIVES: Cutaneous angiosarcoma of head and neck (cAS-HN) is a malignant neoplasm with deficient data on
prognostic factors. The aim of this study is to present our monocenter database on cAS-HN so far and a new
predictive score for locoregional metastasis (LRM). METHODS: Retrospectively, tumor characteristics and
outcome of 103 consecutive patients with cAS-HN were analyzed. The main predictors of LRM (identified by
univariate and multivariate statistics) were combined to a LRM risk score. The prognostic values of stratification
into high-, medium-, and low-risk groups concerning disease-specific survival (DSS), distant metastasis (DM), and
progression-free survival (PFS) were evaluated. RESULTS: LRM (n = 29) and control (n = 74) groups differed
significantly concerning several tumor characteristics and outcome (DM, PFS, and DSS). Patients developing LRM
showed 3-, 5-, and 10-year survival rates of 32%, 16%, and 11% (mean DSS time of 36.7 months [95% confidence
interval (CI) 20.5-52.8]) compared to 81%, 73%, and 69% (mean DSS time of 292.4 months [95% CI 208.4-376.5])
in controls without LRM (P b .001). The main predictors were American Joint Committee on Cancer (AJCC) stage,
tumor extent, and origin of the primary tumor. The LRM risk score revealed significant higher values for the LRM
group [7.14 (SD 1.46) vs 4.88 (SD 1.89), P b .001]. The high-risk group showed significantly higher risk for DM and
more unfavorable DSS and PFS. CONCLUSION: The LRM risk score is a simple way to estimate the risk for LRM
and DM, to stage patients, and to determine treatment options.
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Angiosarcomas of head and neck (AS-HN) are approximately 1% to 2%
of all head and neck soft tissue sarcomas, rare malignant mesenchymal
tumors originating in the endothelium of blood vessels, and due to
their common benign visual appearances are difficult to diagnose.
Sixty percent are cutaneous angiosarcomas (cAS), mainly found in the
capillitium and face in people older than 70 years (cAS-HN) [1,2].
Treatment options vary depending on medical findings such as
metastases and the patient’s condition. As most studies have
approved, initial treatment of choice is surgery combined with
adjuvant radiotherapy [3–6].
Five-year disease-specific survival (DSS) rates vary between 46% and
62%. Important prognostic factors are extent of primary tumor,
resection status, histologic tumor differentiation, and metastases [1–3].
Due to aggressive growth and delayed diagnosis, mainly, in AS,
16% to 45% of patients are diagnosed with initial distant metastasis(DM) [7–10]. In their study on cAS-HN, Guadagnolo et al. [3]
excluded patients with initial metastases. Here, 25 patients (36%)
developed DM, especially in the lung. Eleven patients (16%) had,
,
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who developed metastases. Both studies found no significant
predictive factors for metastasis. Of 80 patients with cAS-HN in
our Cancer Centre, we described 13 with initial DM, 16 with
secondary DM, and 27 with locoregional metastasis (LRM). [2] In
this study, we add 23 further consecutive patients to broaden the
database. In our abovementioned previous study, prevalence of LRM
was only reported shortly in a descriptive manner. Assessment of risk
factors for LRM and development of risk stratification were not
performed at all. Analyzing LRM risk may be of prognostic and
therapeutic relevance in this rare tumor entity.Patients and Methods
Patients
Consecutive patients with cAS-HN treated surgically between
1980 and 2013 were retrospectively identified from our institutional
database. This study was approved by the local ethics committee
(Ethical Committee of the Westphalian Wilhelms-University
Muenster, Approval No. 2014-528-f-S) and was conducted in
accordance with the Guidelines for Good Clinical Practice and in
compliance with the Declaration of Helsinki. All participating
patients provided written informed consent.
Inclusion criteria for this study were histopathologic secured
sporadic cAS-HN and a minimum follow-up time of 6 months.
Exclusion criteria were patients suffering from multiple cancers of the
head and neck, patients after other malignancies in the head and neck,
and patients who had already received cancer or lymph node surgery
(e.g., neck dissection). Patients with cAS-HN arising in lymphoe-
dema or after radiation were also excluded from the study. All patients
received complete appropriate staging, including ultrasonography of
relevant lymph node levels and abdomen and radiologic imaging
[computed tomography (CT) or magnetic resonance imaging (MRI)
of head, neck, thorax, and abdomen]. Follow-up care (clinical
examination, ultrasonography, CT, or MRI in case of suspicious
findings) was conducted every 3 months in the first 2 years and every 6
months thereafter. Patients who developed regional LRM during the
observation period were classified as the LRM group, and those without
LRM were classified as the control group.Methods
Relevant characteristics and parameters for analysis were performed
comparable to our previous research and are displayed in detail in
Table 1. The main outcome parameters were local relapse (LR),
LRM, DM, progression-free survival (PFS), and DSS.
For continuous variables, the Mann-Whitney U test was used as a
non-parametric test for abnormally distributed data. Categorical
variables were analyzed using the chi-square test and Fisher exact test.
DSS (time from first diagnosis to tumor-dependent death; data on
patients without tumor-dependent death were censored at the last
follow-up time), PFS [time from first diagnosis to disease progression
(LR, LRM, and DM)], LRM time (time from first diagnosis to
LRM), and DM time (time from first diagnosis to DM) were
calculated using the Kaplan-Meier method, and group differences
were analyzed using the log-rank test.
Binary logistic regression analysis (BLR) was used to model the
predictors of LRM. Potential predictors identified by univariate
analysis were entered into a stepwise backward procedure using P b.05 for entry and P N .1 for removal. To create a prediction model for
LRM, only preoperative assessable variables with significant group
differences (P b .05) were considered to be suitable for inclusion in
the BLR. Intraoperative or postoperative parameters were excluded
from the BLR, even if statistically significant. To overcome risk of
overmodeling, we decided to insert only the following three variables
into BLR: localization of the primary tumor, tumor extent, and AJCC
stage. AJCC stage can be interpreted as a composite variable that
includes information on tumor dimension and depth (T classifica-
tion), nodal disease at first diagnosis (N classification), DM at first
diagnosis (M classification), and histologic grading. Because
occurrence of LRM is a time-dependent variable, we also modeled
prediction of LRM time using Cox regression analysis (CRA). The
same three variables that were inserted into BLR were used for CRA.
Development of the prediction models was performed considering
the suggestions of Harrell et al. [11].
Creation of an easy to use LRM risk score was performed by
combining the BLR- and CRA-confirmed predictors of LRM
occurrence. Instead of taking BLR equation itself for risk assessment,
we decided to develop a point assessment for each predictor to enable
easy and quick routine assessment for the clinician (Table 3). By
receiver operating characteristic curve analysis and Youden index
calculation, an optimal cut-off value for the LRM risk score was
defined, and for clinical and prognostic purposes, the study
population was stratified to a three-scale (low, medium, and high)
risk group assessment. Prognostic relevance of LRM risk groups on
DSS, PFS, and DM time was calculated according to Kaplan-Meier
including the log-rank test for the whole study population (n = 103)
and for a smaller sample (n = 90) after exclusion of patients with
primary DM (M1, n = 13).
All statistical analyses were performed by a statistician using the
Statistical Package for Social Sciences, version18.0 (SPSS Inc,Chicago, IL).Results
Overview
In our study, we included 103 patients with cAS-HN, of these 65
males and 38 females. Mean age at first diagnosis was 72.1 ± 13.5 years,
and mean follow-up time was 57.4 ± 83.2 months. Concerning the
overall survival status, 52 people died, while 51 survived, leading to a
mean overall survival status of 155.3 months [95% confidence interval
(CI) 102.6-207.98, median 58.8 (95%CI 49.2-68.5)]; 3-, 5-, 10-, and
20-year survival rates were 61%, 49%, 37%, and 26%. Focusing on the
DSS status, 40 patients died because of the tumor and 12 due to other
reasons. Mean DSS was 220.2 months (95% CI 153.1-287.3), and
median DSS was 174.1 months (95% CI 11.5-336.8) with 3-, 5-, 10-,
and 20-year survival rates of 66%, 55%, 50%, and 44%.
Initial Nodal Disease (N1)
Comparing patients with N1 (n = 10) to those with N0 (n = 93),
gender, age, localization, and tumor size did not differed significantly
(P N .05). Concerning one region of tumor extent, 2 of 57 patients
were diagnosed with N1, while in cAS-HN of two or more regions, 8
of 46 cases were affected (P = .040). Of 23 superficial cAS-HN (TIa
and IIa), none was found to be N1, whereas of 80 deep tumors (TIb
and TIIb) 10 were diagnosed to be N1 (P = .112).
Patients with N1 died more often tumor-dependently (P = .013).
Mean DSS in N1 patients was 15.4 months (95% CI 7.6-23.2)
compared with mean DSS of 238 months (95% CI 166.4-310.1) in
Table 1. Comparison of Assessed Variables between the LRM and Control Groups
Parameter Control (n = 74) LRM Group (n = 29) Significance (P Value)
Age
b70 years n (%) 23 (31.1) 5 (17.2) .219
≥70 years n (%) 51 (68.9) 24 (82.8)
Gender .262
Male n (%) 44 (59.5) 21 (72.4)
Female n (%) 30 (40.5) 8 (27.6)
Disease-specific death b .001
No n (%) 56 (75.7) 7 (24.1)
Yes n (%) 18 (24.3) 22 (75.9)
Origin of primary tumor/localization .030
Face n (%) 46 (62.2) 11 (37.9)
Scalp n (%) 28 (37.8) 18 (62.1)
Extent of primary tumor .004
One region n (%) 48 (64.9) 9 (31.0)
Two or more regions n (%) 26 (35.1) 20 (69.0)
Primary tumor site .566
Scalp n (%) 16 (21.6) 10 (34.5)
Lower third of the face n (%) 1 (1.4) 1 (3.5)
Midface including nose n (%) 27 (36.5) 7 (24.1)
Upper third of the face n (%) 9 (12.2) 2 (6.9)
Ear and periauricular n (%) 6 (8.1) 1 (3.5)
More than one region: face or scalp n (%) 11 (14.9) 5 (17.2)
More than one region: face and scalp n (%) 4 (5.4) 3 (10.3)
Dimension of primary tumor b .001
b5 cm n (%) 41 (55.4) 3 (10.3)
≥5 cm n (%) 33 (44.6) 26 (89.7)
T classification b .001
Ia n (%) 16 (21.6) 0
Ib n (%) 24 (32.4) 3 (10.3)
IIa n (%) 7 (9.5) 0
IIb n (%) 27 (36.5) 26 (89.7)
Tumor depth b .001
Superficial (Ia, IIa) n (%) 23 (31.1) 0
Deep (Ib, IIb) n (%) 51 (68.9) 29
N classification b .001
pN0 n (%) 73 (98.6) 20 (69.0)
pN1 n (%) 1 (1.4) 9 (31.0)
M classification .001
pM0 n (%) 70 (94.6) 20 (69.0)
pM1 n (%) 4 (5.4) 9 (31.0)
Resection status b .001
R0 n (%) 49 (66.2) 3 (10.3)
R1 n (%) 22 (29.7) 23 (79.3)
R2 n (%) 3 (4.1) 3 (10.4)
Safety margin .567
b1 cm n (%) 29 1
≥1 cm n (%) 20 2
LR .117
No n (%) 49 (66.2) 14 (48.3)
Yes n (%) 25 (33.8) 15 (51.7)
DM b .001
No n (%) 62 (83.8) 6 (20.7)
Yes n (%) 12 (16.2) 23 (79.3)
Treatment protocol .001
Surgery alone n (%) 30 (40.5) 4 (13.8)
Surgery + adjuvant radiotherapy n (%) 36 (48.6) 12 (41.4)
Surgery + adjuvant CT n (%) 1 (1.4) 5 (17.2)
Surgery + combined radiochemotherapy n (%) 3 (4.1) 6 (20.6)
Radiotherapy alone n (%) 2 (2.7) 1 (3.5)
CT alone n (%) 0 (0) 1 (3.5)
Combined radiochemotherapy n (%) 2 (2.7) 0 (0)
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65.5% of patients with N0 survived (P b .001). Patients with N1
showed also a high significance for initial and secondary DM (9 of 10
people with N1, P b .001).
LRM in Clinical Course
Table 1 presents differences between the LRM group and the
controls. We found significant differences between both groupsconcerning the dimensions of the primary tumor, TNM
classification, tumor depth, resection status, DM, and treatment
protocol.
Kaplan-Meier analysis of DSS showed 3-, 5-, and 10-year survival
rates of 32%, 16%, and 11% for the LRM group compared to 81%,
73%, and 69% in the control group (P b .001). Mean DSS with
LRM was 36.7 months (95% CI 20.5-52.8, median 17.9), pointing
out a high significance (P b .001) compared to DSS without LRM
Table 2. Statistical Details of the Calculated Prediction Models (BLR and CRA) and Its Variables
Included Variable Significance (P Value) Wald df Exp(B) 95% CI of exp(B)
BLR
Localization (.061) 3.502 1 2.830 0.952-8.410
EPT (.074) 3.201 1 2.724 0.909-8.162
AJCC stage (.063) 10.471 5
IA versus IV (.999) 0.000 1 0.000 —
IB versus IV (.027)* 4.876 1 0.132 0.022-0.797
IIA versus IV (.003)** 8.941 1 0.052 0.007-0.360
IIB versus IV (.087) 2.924 1 0.278 0.064-1.206
III versus IV (.443) 0.587 1 0.442 0.055-3.568
CRA
Localization (.022)* 5.226 1 2.537 1.142-5.636
EPT (.023)* 5.184 1 2.663 1.146-6.187
AJCC stage (b .001)*** 23.148 5
IA versus IV (.975) 0.001 1 0.000 —
IB versus IV (.001)** 11.757 1 0.084 0.020-0.347
IIA versus IV (b .001)*** 16.566 1 0.032 0.006-0.167
IIB versus IV (.001)** 11.619 1 0.189 0.072-0.492
III versus IV (.167) 1.913 1 0.380 0.096-1.498
Significance, statistical significance. *P b .05, **P b .01, ***P b .001, df, degree of freedom.
Localization, scalp/neck versus face. EPT, extent of primary tumor: one versus more than one
anatomic region.
Table 4. Distribution of LNM Risk Scores with regard to LRM Occurrence and Stratification into
LRM Risk Groups
LRM Risk Score LRM Risk Group Control Group (n = 74) LRM Group (n = 29)
n (%) n (%)
2 Low 6 (100.0) −(0.0)
3 Low 18 (94.7) 1 (5.3)
4 Low 10 (100.0) −(0.0)
Total low risk (n = 35) 34 (97.1) 1 (2.9)
5 Medium 9 (75.0) 3 (25.0)
6 Medium 16 (76.2) 5 (23.8)
Total medium risk (n = 33) 25 (75.8) 8 (24.2)
7 High 8 (61.5) 5 (38.5)
8 High 5 (31.3) 11 (68.8)
9 High 2 (33.3) 4 (66.7)
Total high risk (n = 35) 15 (42.9) 20 (57.1)
Table 5. Time to Distant Dissemination (DM Time), PFS Time, and DSS Time with regard to
LRM Risk Stratification Based on the LRM Risk Score
LRM Risk Group
Low Medium High
Total collective (n = 103)
DM time (months)
Mean 377.9 213.6 29.1
Median — — 23.2
95% CI 269.7-486.2 145.6-281.5 18.9-39.4
PFS time (months)
Mean 243.7 134.8 17.5
Median 132.1 16.5 10.9
95% CI 141.3-346.2 70.6-199.1 9.5-25.6
DSS time (months)
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Twenty-three of 29 cases with LRM developed DM (P b .001).
Multivariate Regression Analyses
BLR (prediction of LRM) and CRA (prediction of LRM time)
both proved the prognostic value of all three inserted variables
(localization, tumor extent, and AJCC stage), and all three variables
were included into the BLR and CRA equation models (Table 2).
The BLR model showed good quality with a Nagelkerke's R-square
(a marker of inclusion and prognosis quality) of 0.400 and accurate
classification (predicted vs observed LRM, respectively; no LRM) of
83.5% of all patients. A value of exp(B) (odds ratio) b1 indicates a
reduced risk, whereas values N1 indicate an increased probability.
Therefore, localization of cAS-HN at the scalp and/or neck and
tumor extent over more than one region increase risk of LRM
development and correlate with shorter LRM time. Compared to
AJCC stage IV, especially patients with AJCC stages IA, IB, and IIA
showed significantly reduced risk for LRM occurrence.
LRM Risk Score and Risk Stratification
The three included parameters in the BLR and CRA were
combined to develop a clinically applicable predictive score for LRM
risk (LRM risk score; Table 3). The mean LRM score was
significantly higher in the LRM group [7.14 (SD 1.46; 95% CI
6.58-7.69)] than in the control group [4.88 (SD 1.89; 95% CI
4.44-5.32); P b .001].Table 3. Design and Algorithm for Calculation of the LRM Risk Score Based on Characteristics of
the Primary Tumor (Localization and Extent over Anatomic Regions) and AJCC Stage
Predictive
Variable
Assessed Points Value
0 1 2 3 4
Localization Face Capillitium and
neck
1-2
Tumor extent One region More than one
region
1, 3
AJCC stage IA IIA IB IIB III, IV 0-4
Total 2-9Receiver operating characteristic curve analysis revealed an
optimum cut-off value of 6.5 to differentiate between patients with
or without LRM. Patients with an LRM risk score ≥7 (7-9) were
classified as the high-risk group (LRM risk N30%), while those with
an LRM score b7 (2-6) showed a lower risk for LRM (area under the
curve: 0.819, 95% CI 0.732-0.906). From a clinical point of view,
the latter group can be further divided into a low-risk group (LRM
risk b10%) and a medium-risk group (LRM risk 10-30%). Table 4
shows distribution of LRM risk score values, the risk stratification,
and prevalence of LRM within these subgroups.
Prognostic Value of LRM Risk Stratification
After stratifying the study population according to the LRM risk
score into low, medium, and high risks, we found significant
differences between these groups concerning time-dependent out-
come variables (Table 5). Patients with high LRM risk had a
significantly shorter time to DM (DM time; Figure 1), PFSMean 331.9 198.2 31.3
Median — — 23.7
95% CI 222.7-441.2 128.8-267.6 10.7-41.8
Without M1 (n = 90)
DM time (months)
Mean 377.9 211.6 40.0
Median — — 36.0
95% CI 269.7-486.2 143.4-279.8 27.1-52.9
PFS time (months)
Mean 243.7 130.5 22.7
Median 132.1 13.3 12.4
95% CI 141.3-346.2 66.7-194.2 11.9-33.5
DSS time (months)
Mean 331.9 197.4 41.9
Median — — 40.7
95% CI 222.7-441.2 128.0-266.9 27.7-56.1
DM time, time to DM.
Figure 1. Cumulative hazard function for DM in different LRM risk groups. All group differences were statistically significant (high vs low:
P b .001; high vs medium: P = .003; medium vs low: P = .013).
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Table 5, these differences were also assessable in a smaller study
sample of n = 90 patients after exclusion of patients who initially
showed distant dissemination (M1, AJCC stage IV).
Discussion
In cAS-HN, little is known about metastatic spread. There are single
case reports and studies that often include AS with origin of other body
sites besides head and neck as well with AS due to radiation and
lymphatic obstruction.With 103 patients, our retrospective study is the
largest monocenter study on spontaneous cAS-HN to date [1,3,6].
Guadagnolo et al. [3] found a significantly reduced DSS for
patients with a tumor located at the scalp and N5 cm. This correlatesFigure 2. Kaplan-Meier curve for PFS time in different LRM risk gro
group (high vs low: P b .001; high vs medium: P = .015; medium vswell with our findings concerning LRM. Apparently, tumor depth
was a significant risk factor for LRM: 29 cases with a deep tumor (Ib,
IIb) lead to LRM, while none of the superficial cAS-HN (in total 23)
metastasized. This has not been reported previously in this way, and
examining tumor depth can be done easily.
BLR and CRA found three significant parameters to predict LRM:
origin and extent of primary tumor together with the AJCC stage.
The big advantage of the AJCC staging is that it is a standardized and
well-established method that includes multiple factors: size, depth,
lymph node involvement, DM, and histologic grading. On the
downside, tumor depth is equalized in AJCC because every stage
includes superficial and deep tumors. Instead of AJCC, we used its
single parameters alone such as tumor depth with BLR and CRA, butups. Statistically significant unfavorable outcome for the high-risk
low: P = .056).
Figure 3. Kaplan-Meier curve for DSS time in different LRM risk groups. All group differences were statistically significant (high vs low: P b
.001; high vs medium: P = .002; medium vs low: P = .029).
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shown). Furthermore, we choose AJCC stage instead of multiple
single or further histologic parameters to avoid overmodeling.
With the three stated significant variables, we created an LRM risk
score to predict the risk of LRM and its impact on DM, PFS, and
DSS. We estimated three different clinical groups concerning LRM
risk: low, medium, and high risks, interestingly with almost the same
size (low: n = 35, medium: n = 33, high: n = 35). Of the low-risk
group, only one person developed LRM, while of medium risk 8
patients (24.2%) and of high risk 20 patients (57.1%) were eventually
diagnosed with LRM. As shown in Figures 1 to 3, the low risk group
had the best results for DM, PFS, and DSS. After 30 months, e.g.,
hazard forDM in the high-risk groupwas twice as high as in the low-risk
group. This kind of risk stratification was not reported previously.
There are other similar scores, for example, for metastatic colorectal
cancer and prostate cancer risk assessment [12,13]. Although these
tumors present total different entities, development and design of
these clinical risk scores have a lot in common with our LRM score.
Both scores have already proven its prediction values and its simplicity
over the last decade [14,15]. This fact illustrates the possible clinical
value of such risk scores.
Of course, certain limitations in this study have to be mentioned,
including the retrospective design. Our LRM risk prediction score
needs to be confirmed and validated internally and externally in an
independent data set in further prospective controlled studies. Due to
the fact that cAS-HN is a rare disease, our prediction model is only
based on a discovery cohort, and a validation cohort is missing. This is
a clear shortcoming of our study. Nevertheless, in our opinion, it is
important to present our results to facilitate validation of our score by
other researchers. Furthermore, the inclusion of patients with
follow-up times less than the median time to LRM is a probable
error source to the predictive model.
Conclusion
For cAS-HN, no common and consistent guidelines for diagnosis and
treatment are available. Our LRM score is a simple and implemen-
table way for the clinician to stage patients and to determinetreatment options. With three parameters, the risk for LRM can be
estimated and therefore the risk for DM. The medium- and high-risk
groups might subsequently profit from neck dissection, local
radiotherapy of draining the lymphatic area, or adjuvant CT.
Compared to other scores, it is also very simple to use and may
affect the decision of treatment options. Nevertheless, additional
validation of the score has to be accomplished. For the future, a
coherent classification of cAS-HN patients will be possible, and
because of the few numbers of affected patients, data collection of
multicenter studies will be simplified. With it, further (prospective)
studies especially on treatment can be arranged to find a common
treatment strategy for patients with cAS-HN.
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